Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney transplant drug linked to diabetes risk — study seeks answers

NCT ID NCT06833463

Knowledge-focused Sponsor: Chiesi Poland Sp. z o.o. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why some kidney transplant patients develop blood sugar problems like diabetes. It focuses on how the body processes the drug tacrolimus, which helps protect the new kidney but can also raise blood sugar. Researchers will follow 120 adults in Poland to find out which factors increase the risk of diabetes after transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult kidney graft receipients transplanted in the participating study sites

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Recipients of a kidney transplant from a living or deceased donor * Standard immunosuppressive regimen post-kidney transplantation (KTx) including Envarsus® * LCP Tacrolimus therapy initiated from the day of KTx or conversion from another tacrolimus formulation to LCP Tacrolimus by day 8 at the latest, according to the institution's routine practice * Informed patient consent to participate in the study Exclusion Criteria: * Diagnosis of diabetes (type 1 or type 2) treated with diet or glucose-lowering drugs * Random glycemia/HbA1c levels justifying a diagnosis of diabetes at the time of study enrollment * Kidney retransplantation * Recipients of a multi-organ transplant * Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss * Use of flozins for renal or cardiac indications * Chronic use of drugs affecting carbohydrate metabolism, such as glucocorticosteroids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Department of Nephrology, Dialysis, Transplantology and Internal Medicine

    RECRUITING

    Krakow, 30-688, Poland

  • Department and Clinic of Nephrology and Transplantation Medicine, University Clinical Hospital

    RECRUITING

    Wroclaw, 50-556, Poland

  • Department and Clinic of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw

    NOT_YET_RECRUITING

    Warsaw, 02-097, Poland

  • Department of Internal Diseases and Transplant Nephrology, Medical University of Lodz

    NOT_YET_RECRUITING

    Lodz, 90-153, Poland

  • Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk

    RECRUITING

    Gdansk, 80-952, Poland

  • Department of Transplantology and General Surgery, Provincial Hospital

    RECRUITING

    Poznan, 60-479, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.